Complications of myeloma and its treatments

Hemostatic Abnormalities in Multiple Myeloma Patients. Gogia A et al. Asian Pac J Cancer Prev. 2018 Jan 27;19(1):127-130. Incidence of Second Primary Malignancies after Autologous Transplantion for Multiple Myeloma in the Era of Novel Agents. Sahebi F et al. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30021-1. doi: 10.1016/j.bbmt.2018.01.006. [Epub ahead of print]. Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem…

Details
Journal, Library, Management of complications & side effects

Biology and genetics

Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics. Kamande JW et al. Integr Biol (Camb). 2018 Jan 26. doi: 10.1039/c7ib00183e. [Epub ahead of print]. Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib…

Details
Journal, Library, Management of Myeloma

Results from TEAMM clinical trial reported

Results from the Phase III TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) trial have recently been reported at the American Society of Haematology 2017 conference. This study assessed the benefit of levofloxacin antibiotic prophylaxis and its effect on healthcare associated infections in newly diagnosed myeloma patients. The results show that levofloxacin prophylaxis had a…

Details
News

Carfilzomib treatment associated with cardiovascular events in myeloma patients

A meta-analysis conducted by researchers at the University of Pennsylvania has shown that treatment with carfilzomib (Kyprolis®) is associated with a higher incidence of cardiovascular events in myeloma patients. The study found that 18.1% of myeloma patients receiving carfilzomib experienced cardiovascular events, including hypertension, cardiac arrest, cardiac failure and arrhythmias, compared to only 3.8% of…

Details
News

Supportive treatments

Mobilization of Hematopoietic Progenitor Cells with Standard or Reduced Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients. a Randomized Prospective Single Center Phase II Study. Samaras P et al. Biol Blood Marrow Transplant. 2017 Dec 12. pii: S1083-8791(17)31679-8. doi: 10.1016/j.bbmt.2017.12.775. [Epub ahead of print]. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.…

Details
Journal, Library, Myeloma Prognosis & Outcomes

Related conditions

Pattern of care and impact of prognostic factors on the outcome of head and neck extramedullary plasmacytoma: a systematic review and individual patient data analysis of 315 cases. Venkatesulu B et al. Eur Arch Otorhinolaryngol. 2017 Dec 9. doi: 10.1007/s00405-017-4817-z. [Epub ahead of print]. Case Report: Treatment of Light Chain Amyloidosis with Daratumumab Monotherapy in Two Patients. Gran…

Details
Library

General

Falls in Older Adults with Multiple Myeloma. Wildes TM et al. Eur J Haematol. 2017 Dec 14. doi: 10.1111/ejh.13009. [Epub ahead of print]. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations From the Organizing Committee. Holstein SA et al. Biol Blood Marrow Transplant. 2017 Dec 11. pii: S1083-8791(17)31678-6. doi: 10.1016/j.bbmt.2017.12.774. [Epub ahead of print]. Multiple Myeloma and Bone:…

Details
Journal, Library

Emerging treatments

A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma. Ri M et al. Intern Med. 2017 Dec 8. doi: 10.2169/internalmedicine.9567-17. [Epub ahead of print]. Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. Meyers DE et al. Blood Cancer J. 2017 Dec 5;7(12):640. doi: 10.1038/s41408-017-0020-0.…

Details
Journal, Library

Diagnostic techniques and prognostic indicators

Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient. Sachpekidis C et al. Diagnostics (Basel). 2017 Dec 15;7(4). pii: E61. doi: 10.3390/diagnostics7040061. Predictive value of 18 F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma. Tu…

Details
Diagnosing and Monitoring Myeloma, Journal, Library